Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
RTS,S: the first malaria vaccine
Fidel Zavala
Fidel Zavala
Published January 4, 2022
Citation Information: J Clin Invest. 2022;132(1):e156588. https://doi.org/10.1172/JCI156588.
View: Text | PDF
Viewpoint

RTS,S: the first malaria vaccine

  • Text
  • PDF
Abstract

Authors

Fidel Zavala

×

Figure 1

Impact of RTS,S vaccine on malaria infection and transmission.

Options: View larger image (or click on image) Download as PowerPoint
Impact of RTS,S vaccine on malaria infection and transmission.
Vaccinati...
Vaccination with RTS,S induces antibodies against circumsporozoite protein (CSP), which is expressed by sporozoites, the infective form of Plasmodium that mosquitos transmit. During infection in unvaccinated individuals, sporozoites travel to the liver, where they move through hepatocytes and differentiate to hepatic merozoites. CSP is expressed in the early liver stages, but not by liver stage merozoites. Antibodies to CSP following RTS,S vaccination immobilize the sporozoites, thereby preventing infection of hepatocytes. RTS,S-induced protection from infection and severe disease wanes over time and correlates with the level of anti-CSP antibodies. RTS,S-induced immune responses do not interfere with the infectivity of Plasmodium gametocytes to mosquitoes. Even following vaccination, most children will carry parasites that will infect mosquitoes; thus, transmission in the population will remain unchanged. Image adapted from Raphemot et al. (19).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts